MediWound (MDWD)
(Delayed Data from NSDQ)
$17.70 USD
+1.35 (8.26%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $17.73 +0.03 (0.17%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$17.70 USD
+1.35 (8.26%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $17.73 +0.03 (0.17%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Zacks News
MediWound (MDWD) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
MediWound (MDWD) delivered earnings and revenue surprises of 42.11% and -17.97%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate MediWound (MDWD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MediWound (MDWD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
MediWound (MDWD) delivered earnings and revenue surprises of 25.00% and 7.96%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
4 Drug Stocks Poised to Surprise this Earnings Season
by Zacks Equity Research
Market sentiment seems to be improving courtesy of raised outlooks, new product approvals and encouraging pipeline updates.
Why Earnings Season Could Be Great for MediWound (MDWD)
by Zacks Equity Research
MediWound (MDWD) looks like an exciting pick for investors as it is poised to beat at earnings season.
Earnings Estimates Moving Higher for MediWound (MDWD): Time to Buy?
by Zacks Equity Research
MediWound (MDWD) could be a solid choice for investors as it has seen estimates moving sharply higher over the past four weeks.
Bear of the Day: Valeant Pharma (VRX)
by Brian Hamilton
The company is facing legal, accounting, and negative pricing issues.